Form 4: Terns Pharmaceuticals Director Option Cancellation

Director Radhika Tripuraneni reports the cancellation of stock options following the acquisition of Terns Pharmaceuticals by Merck.

Summary

• Director Radhika Tripuraneni reported the cancellation of multiple tranches of stock options.
• The cancellation occurred on May 5, 2026, following the completion of the merger between Terns Pharmaceuticals and Merck Sharp & Dohme LLC.
• Options were converted into the right to receive the cash difference between the $53.00 per share merger consideration and the respective exercise prices of the options.
• A total of 190,030 options with exercise prices ranging from $2.13 to $34.60 were cancelled.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final stages of a completed corporate acquisition.

Positives

• The merger provides shareholders and option holders with a cash exit at $53.00 per share.

Negatives

• The company is no longer an independent publicly traded entity following the acquisition.

Risks

• No ongoing operational risks as the company has been acquired.

Future Outlook

The company has been acquired by Merck; therefore, no further independent forward-looking guidance is provided.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 24, 2026.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of a significant M&A event in the biopharmaceutical sector, reflecting the ongoing trend of large-cap pharmaceutical companies acquiring smaller biotech firms to bolster their clinical pipelines.

Comparison to Industry Standards

• The $53.00 per share cash acquisition is consistent with standard exit premiums observed in recent mid-cap biotech acquisitions by major pharmaceutical entities like Merck.

Stakeholder Impact

• Shareholders and option holders receive cash consideration for their equity interests.

Next Steps

• Final delisting of Terns Pharmaceuticals common stock from public exchanges.

Key Dates

Keywords

Terns Pharmaceuticals, Merck, Merger, Acquisition, Form 4, Insider Transaction, Stock Options